Mod GRF 1-29 & GHRP-2 Blend
A research blend pairing Mod GRF 1-29 with GHRP-2 for potent synergistic GH release. Functionally identical to CJC-1295 & GHRP-2 Blend but labeled under the Mod GRF 1-29 nomenclature.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. Mod GRF 1-29 & GHRP-2 Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Same mechanism as CJC-1295 + GHRP-2
- Strong GH pulse amplitude
- Moderate cortisol/prolactin profile (better than GHRP-6)
- Mod GRF 1-29 & GHRP-2 Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Same mechanism as CJC-1295 + GHRP-2
- Strong GH pulse amplitude
- Moderate cortisol/prolactin profile (better than GHRP-6)
- Well-studied combination in research literature
What is Mod GRF 1-29 & GHRP-2 Blend?
Tap any underlined term for an instant definition.
The Mod GRF 1-29 & GHRP-2 Blend is functionally identical to the CJC-1295 (no DAC) & GHRP-2 blend, listed separately because researchers often use either "CJC-1295" or "Mod GRF 1-29" interchangeably to refer to the 4-substitution GHRH analogue without DAC modification.
What It Is
- Mod GRF 1-29 = CJC-1295 without DAC: GHRH 1-29 with Ala2, Gln8 and two additional substitutions for DPP-IV resistance; half-life ~30-60 min
- GHRP-2: potent GHS-R1a agonist; strong GH output with moderate cortisol/prolactin effects
- Identical mechanism and expected outcomes to CJC-1295 (no DAC) + GHRP-2
Mechanism, Research Findings, and Dosing
- Identical to CJC-1295 & GHRP-2 Blend
- GH peaks 40-60 ng/mL in responsive subjects at standard doses
- IGF-1 elevation 60-80% above baseline at 3 months
- Cortisol: transient 20-25% elevation at peak concentration
Dosing From the Literature
- Mod GRF 1-29 100-200 mcg + GHRP-2 100-200 mcg per injection
- Twice daily on empty stomach
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 30 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Mod GRF 1-29 & GHRP-2 Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection on empty stomach.
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & Ipamorelin Blend
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.